Manufacturing makes CAR-T possible. Hospitals make CAR-T scalable. CAR-T's biggest commercialization challenge isn't manufacturing alone. Hospital capacity—from patient selection and leukapheresis to CRS management and reimbursement—may be the real bottleneck limiting market expansion.
In the previous articles, I discussed the manufacturing (CMC) and vein-to-vein supply chain challenges behind CAR-T. But even if a CAR-T company successfully solves its manufacturing problems, that doesn't necessarily mean it can rapidly expand the market.
The reason is: CAR-T is not just a drug—it is an integrated healthcare service.
From patient selection, cell collection, manufacturing, bridging therapy, and lymphodepletion, to infusion, intensive monitoring, and long-term follow-up, every patient's treatment requires extensive coordination across multiple hospital departments.
This means that beyond Manufacturing Capacity, Hospital Capacity is another major bottleneck that limits CAR-T commercialization.
ShaoChi CHENG
CAR-T is not a treatment that every patient can receive.
Hospitals must evaluate whether a patient meets the approved indication, has undergone sufficient standard therapies, has active infections, possesses adequate organ function, and is physically fit enough to tolerate treatment.
In addition, many CAR-T patients have already received multiple lines of therapy. Their immune systems are often severely compromised, which may reduce the quality of the harvested T cells and ultimately affect manufacturing success and clinical outcomes.
For this reason, patient selection is the very first step toward a successful CAR-T treatment.
CAR-T doesn't just test physicians—it tests the entire hospital.
A single patient's treatment often involves hematologists, the leukapheresis team, blood bank, pharmacy, cell processing laboratory, neurologists, intensive care specialists, and quality management personnel.
Dozens of healthcare professionals may participate throughout the treatment journey.
A delay at any point can disrupt the entire schedule; it means cross-department coordination is one of the most important factors for successful CAR-T treatment.
The first step of CAR-T is not drug infusion—it's collecting the patient's T cells.
Leukapheresis requires dedicated equipment, specially trained staff, and careful scheduling.
If collection equipment is unavailable, the patient's condition deteriorates, or the harvested cells are of insufficient quality, the entire treatment timeline may be delayed.
Leukapheresis is therefore much more than a blood collection procedure—it is a key component of hospital treatment capacity.
Manufacturing CAR-T cells typically takes 2–4 weeks.
Cancer, however, does not stop progressing while the cells are being manufactured.
Hospitals therefore often provide Bridging Therapy to keep the disease under control during this waiting period.
This requires careful clinical judgment.
If treatment is too weak, the disease may progress rapidly. If treatment is too aggressive, the patient's condition may worsen and reduce the effectiveness of the subsequent CAR-T therapy.
Bridging therapy is not simply "waiting"—it is about maintaining the optimal balance between disease control and preserving the patient's ability to benefit from CAR-T.
A few days before CAR-T infusion, patients usually receive lymphodepleting chemotherapy using agents such as Fludarabine and Cyclophosphamide.
The purpose is not to kill the cancer directly. Instead, lymphodepletion creates a more favorable environment for the incoming CAR-T cells.
The body already contains a large population of native T cells that compete with CAR-T cells for cytokines such as IL-7 and IL-15, nutrients, and physical space. They may also contribute to the elimination of the infused CAR-T cells.
By temporarily reducing these competing immune cells, lymphodepletion allows CAR-T cells to expand more effectively and achieve stronger anti-tumor activity.
A useful analogy is a military operation.
CAR-T cells are the elite special forces, while lymphodepletion clears the battlefield and secures the supply lines before they arrive.
Lymphodepletion also tightly links hospital operations with manufacturing and logistics.
If manufacturing is delayed, cryogenic transportation encounters problems, or the patient develops an infection after chemotherapy and cannot receive infusion on schedule, the entire treatment plan may need to be reorganized.
This illustrates an important point:
CAR-T is not simply a product that can be delivered once manufacturing is complete. It is an integrated system where manufacturing, logistics, and hospital operations must remain synchronized.
Even after the CAR-T product arrives at the hospital, several critical procedures remain.
The hospital must verify cryogenic shipping conditions, confirm patient identity, thaw the product correctly, and ensure that the patient is clinically stable.
If the patient develops an infection, fever, or other serious complications, treatment may need to be postponed—even when the product has already arrived.
Cytokine Release Syndrome (CRS) is one of the most common and clinically significant side effects of CAR-T therapy.
Symptoms range from fever and hypotension to severe shock and multi-organ failure.
Hospitals therefore must possess comprehensive monitoring capabilities, including ICU support, access to Tocilizumab, corticosteroids, and healthcare professionals specifically trained in CRS management.
Not every hospital has these capabilities, making CRS management a major requirement for becoming a certified CAR-T treatment center.
Besides CRS, ICANS represents another serious complication requiring close attention.
Patients may develop speech impairment, confusion, seizures, or even cerebral edema.
Neurologists and intensive care specialists must continuously evaluate and manage these neurological complications.
CAR-T is not only about treating cancer—it also tests whether a hospital can safely manage high-risk immune-related toxicities.
Not every hospital is authorized to provide CAR-T therapy.
In many countries, treatment centers must complete regulatory certification, manufacturer-required training, and establish comprehensive quality systems before they can administer CAR-T products.
As a result, the size of the CAR-T market is also limited by the number of qualified treatment centers.
Many people believe the CAR-T market is constrained mainly by limited indications or insufficient manufacturing capacity.
However, another critical limitation is often overlooked: the hospital itself.
CAR-T treatment involves leukapheresis, bridging therapy, lymphodepletion, infusion, and intensive monitoring for complications such as CRS and ICANS.
Only hospitals with experienced multidisciplinary teams, specialized equipment, and advanced critical care capabilities can deliver this therapy safely.
In Taiwan, for example, CAR-T treatment is currently concentrated in large academic medical centers.
Therefore, even if future indications continue to expand, the overall CAR-T market will remain constrained unless hospital capacity grows alongside manufacturing capacity.
A simplified CAR-T treatment journey looks like this:
Patient Selection
↓
Hospital Evaluation
↓
Leukapheresis
↓
Manufacturing
↓
Hospital Coordination
↓
Lymphodepletion
↓
CAR-T Infusion
↓
CRS / ICANS Management
↓
Long-Term Follow-up
In previous articles, I explained that Manufacturing Capacity determines how many CAR-T products can be produced.
ShaoChi CHENG
However, even if manufacturing proceeds flawlessly, patients still cannot receive treatment if hospitals lack sufficient staff, equipment, or operational capacity.
Ultimately, Manufacturing Capacity and Hospital Capacity together determine the true commercial capacity of CAR-T.
Beyond clinical capability, hospitals also face significant financial pressure. A single CAR-T treatment costs substantially more than conventional drugs.
In many healthcare systems, hospitals must first purchase the CAR-T product from the manufacturer before receiving reimbursement from government agencies or insurance payers.
If reimbursement is delayed, hospitals must absorb the cost upfront, placing considerable pressure on cash flow. As a result, a hospital's financial strength can influence whether it is willing to offer CAR-T therapy.
This is one of the reasons why CAR-T treatment today remains concentrated in large academic medical centers rather than community hospitals.
CAR-T has transformed cancer treatment. However, what it truly challenges is the entire healthcare system.
Traditional drug commercialization mainly depends on pharmaceutical companies increasing production, hospitals purchasing the drug, and physicians prescribing it.
CAR-T is fundamentally different.
It is a cross-organizational healthcare service that requires synchronized GMP manufacturing, cryogenic logistics, multidisciplinary hospital coordination, intensive care capabilities, and reimbursement systems.
From a business perspective, what limits CAR-T market expansion is not only Manufacturing Capacity, but also Hospital Capacity.
The next generation of competition will not simply be about designing a better CAR. It will be about building a healthcare delivery model that is scalable, reproducible, and economically sustainable.
Manufacturing Capacity + Hospital Capacity = Commercial Capacity
Only when the industry begins treating the healthcare system as part of the product itself—not as a challenge to address after launch—will CAR-T have the opportunity to achieve truly large-scale commercialization.
